Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Journal of Clinical Oncology

Volumn 35, Issue 34, 2017, Pages 3792-3794

  Carlino, Matteo S ^a   Sandhu, Shahneen ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER SIZE; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; IMMUNOTOXICITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; SKIN TUMOR;

HUMANS; IPILIMUMAB; MELANOMA; NIVOLUMAB; SKIN NEOPLASMS;

EID: 85035812835     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.75.2055     Document Type: Editorial

References (9)

1. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
2. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
3. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
5. Schadendorf D, Wolchok JD, Hodi FS, et al: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807-3814, 2017
6. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 16:522-530, 2015
7. Ascierto PA, Del Vecchio M, Robert C, et al: Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 18:611-622, 2017
8. Blank C, van Akkooi A, Rozeman EA, et al: (Neo-)adjuvant ipilimumab 1 nivolumab (IPI 1 NIVO) in palpable stage 3 melanoma—initial data from the OpACIN trial. Ann Oncol 27:LBA39, 2016 (suppl 6)
9. Long GV, Atkinson V, Cebon JS, et al: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial. Lancet Oncol 18:1202-1210, 2017